|
|
|
- れいな なぐも
- 7 years ago
- Views:
Transcription
1
2
3 IgE 1960 % %, % % 20 IgE 21 90% IgE IgE (%)
4 30 IgE 2. 3
5 1. B IgE T IgE IgE IgE 2 T IgE B IgE Th2 IgE Th1 Th1 Th2 Th1 IgE Th2 B IgE IL-4 T IL-12 Th2 Th1 IL-4, IL-13 IL-5, IL-10 IFN IL-2 IgE IgE B IgE IL-X = X 4 3. Th1 Th2 Th1 Th1 20 Th1 IgE Th2 1g 30 g B IgE IgE IgG 10 Th2 4 B IgE IgG IgA Th1 B IgE 2. IgE IgE 4
6 5 IgE IgE IgE 3. 1 Coombs 5 IgE IgE 4 Th2 B T IgE 6
7 50% 5% 10% 10 Th2 Th IgE T T Th2 Th
8 1. IgE 1996 IgE IgE IgG IgE IgE IgG IgE IgE IgE IgE IgE IgE 9 IgE 10 IgE IgE RAST (radio-allergo-solvent test) IgE IgE CAP-FEIA Alastat LUMIWARD Mast CAP 7
9 RAST 3 LUMIWARD CAP-FEIA MAST IgE IgE IgE IgE mm 5mm IgE IgE (C5a) Th2 (fmlp) CC (MCP-3 ) 3 &
10 1-10ng/ml CAP-FEIA 90% - 2. IgE IgE IgE 6 2,3 IgE IgE ECP IgE IgE IgE ECP (eosinophil cationic protein) ECP ECP ECP 13 ECP 9
11 mm Der 1 4 Der 1) g g Der 1 1g 9.46 g 1g 1.97 g 1g Der 1 2 g IgE 10 g ml 0.1ml 0.2ml 0.3ml 0.4ml 0.5ml ml 0.1ml 0.2ml 0.3ml 0.4ml 0.5ml 50% IgG IgE Th1 2. T IgE 10
12 B IgE 11
13 12 20 T Th
14 1. 20 mg/ml 1 mg/ml 13
15 2. 3. IgE 90% IgE IgE 70% 6% IgE A B C IgE IgE B C IgE 14
16 100% 90% 80% 70% T 5 major basic protein (MBP) eosinophil cationic protein (ECP) 2 P A 15
17 5 IgE 4. 90% 5 T T Th IgE 5 5 T IgE IgE T T 5 Th A2 Th2 Th IgE 5 16
18 T IgE RS cm RS ICAM-1 ICAM-1 RS ICAM-1 ICAM Mossad SB. Br. Med. J. 317:33,
19 IgE IgE RS RS 3 IgE 5 IgG2 IgG2 2 IgG2 cystic fibrosis 6. 1 PEF 18
20 NIH ml % T Th
21 IgE IgE Der 1 1g Der 1) Der 1) g/g IgE IgE Nishioka K, JACI IgE IgE IgE 1 IgE 20
22 2-3 3 RS 3 IgE 2 2,3 IgE RS IgE IgE
23 Der 1 1g 2 g IgE 10 g % ACTH (NK) 22
24 IgE 20 ECP T
25 BDP BDP 400 g 5cm 4cm 4cm T ATP AMP 5 -AMP A T
26 g BDP AMP AMP (5-20 g/ml) 2 2 AMP 25
27 26
28 2 1 1 RS RS IgE 85%
29 RS 29 RS
30 RS 3 RS ICAM-1 ICAM-1 IgE 7 T (Th2 ) Th Th1 Th
31 T 1 T B
32 3 90%
33 % 10% % 2% 1977 Hanifin 32
34 1994 Hanifin IgE IgE IgE IgE IgE T T IgE IgE
35 2. T T T IgE T Th1 Th1 IgG
36 Th1 3. IgE IgE IgE IgE IgE Th1 IgE Th2 20% T IgE IgE T IgE IgE IgE
37 IgE IgE IgE IgE 4. IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE 1 cm
38 37 95% Th1 Th2 IgE IgE IgE IgE T 35. T IgE T
39 5 T 38
40 A. B. B 39
41 2g 20g ,3 7,8 IgE IgE IgE 4 40
42 37. T T IgE IgE IgE 1 5, ,000 4,5 IgE
43 IgE IgE IgE IgE 7. 1) 1,1 IgE IgE IgE P P IgE 42
44 P IgE 80 2) IgE T T 43
45 44 1. IgE 1 7% 25% 2% 8% IgE
46 IgE IgE 30% IgE IgE 2,3 IgE 3. IgE 45
47 IgE Sampson IgE CAP-FEIA IgE 2-9kU/ml 90% 65kU/ml IgE IgE
48 1-2 IgE 3 IgE IgE 5,000 Hong IgE T T Th1 Th2 Th1, Th2 47
49 1. IgE
50 eotaxin
51 IgE 25 30% 70% 10 IgE 10,000IU/ml 1 IgE IgE 1 IgE 30 IgE IgE IgE IgE / DNA RNA mrna IgE 40 DNA RNA mrna mrna 6 13 mrna mrna RNA mrna 50
52 mrna mrna IgE TTACCCA TTAGCCA GeneChip, 1.2 cm mrna 42 DNA GeneChip) 41 Affymetrix DNA GeneChip 1.2cm 6, DNA CAGAGCTTG CAGTGCTTG CAGAGCTTG CAGTGCTTG GTCTCGAAT GTCACGAAT GTCTCGAAT GTCACGAAT CAGAGCUUG mrna CAGUGCUUG CAGAGCUUG CAGUGCUUG CCR5 SNP 43 SNP 44 SNP DNA 2000 mrna DNA 1% 1% 2,3 DNA DNA DNA 4 (single nucleotide polymorphism 51
53 SNP: ) 1 SNP SNP SNP 21 DNA 10 SNP: A SNP: B 45 52
54 SNP IgE IgE = Th1 IL-4, IL-13 IL-5, IL-10 Th2 Th2 IgE Th1 T IL-12 IFN B IgE Th2 Th1 IL-2 IL-X = X 47. DNA Th1 46 SNP CpG DNA Th1 Th1 Th1 CpG CpG CpG Th1 Th2 DNA DNA mrna 53
55 90% cystic fibrosis SNP 20 1 cystic fibrosis 30 SNP SNP SNP SNP SNP SNP 54
56 ,
57 1. T 1923 Coca IgG IgE 5, IgE 1966 IgE IgE 100 IgG IgE IgE 2. DNA B IgE 5% T T Thymus T T T T Th1 Th2 56
58 B Bursa B 1 B T IgE IgG Th1 Th2 2 T 1 Th1 2 Th2 Th Th1 Th1 12 Th2 100 IgE Th1 Th2 B B antigen antibody B IgG, IgA, IgM, IgE 4 IgG 1ml 13mg IgE 1ml 0.01mg Th2 B B B 4 13 IgE VCAM-1 Th1 B IgE T IgG IgG2 Th DNA CpG 2. IgE IgE Coombs Coombs Gell 1963 IgE IgE 57
59 IgG IgM SLE T 48 A2 C4, D4 C4 D4 3. Th2 Th1 Coombs GM-CSF IgG IgM 3 5 T B T T Th1 Th2 T T T B T 58
60 Th2 ECP C4 3 GM-CSF IgG IgE 0.5% IgE C4 B4 PAF 1 CC CXC CC eotaxin TNF 1 ICAM VCAM-1 ICAM-1 VCAM-1 59
61 DNA mrna major basic protein (MBP) eosinophil cationic protein (ECP) P A 4. 6 IgG2 IgG 4 IgG2 IgA IgE 2 ICAM-1 1 TNF 20-30nm RNA RS nm 60
62 AMP AMP Der 1 IgE Der 1 (1-10 ) Der p 1 Der f 1 Der ACTH 61
63 ACTH (NK) 12 Th1 0.9%NaCl 8. AMP 2 ATP AMP AMP A AMP AMP AMP DNA
64 IgE T T T 0.01% T 20% Th1 IgE Th2 IgE IgE Coombs T Th T T 63
65 1980 A FK506 FK ) IgE IgE IgE IgE IgE IgE IgE IgE B T DNA SLE, 2) 1. B Gad c 1 IgE Gad c 1 IgE Gad c Eotaxin MCP-1, RANTES MIP-1 CC. 4 DNA DNA A T G C A T G C DNA mrna 64
66 RNA mrna DNA RNA mrna T U mrna DNA RNA G C C G A U T A mrna mrna DNA mrna mrna 1 =1 DNA mrna transcription DNA 1.2cm 20 Affimetrix GeneChip cdna mrna Stanford cdna DNA mrna DNA SNP DNA mrna DNA mrna mrna mrna DNA DNA RNA DNA A T G C 4 RNA U A T(U), G C
67 IgE Nakagomi T, et al. Lancet 343: 121,1994. Erb KJ. Immunol. Today. 21: ,1999. Barnes KC, Marsh DG. Immunol. Today 19: 325, : 27, Greenberg RA et al. J. Pediatr. 114: 774, Murray AB et al. J. Allergy Clin. Immunol. 91: 102, Sporik R. et al. N. Eng. J. Med. 323:502, Kivity S et al. J Allergy Clin Immunol 91:844,1993. Platts-Mills TAE et al. Lancet 2:675,1982. Arshad SH et al. Lancet 339:1493, Nishioka K, et al. J. Allergy Clin. Immunol. 101:28, Iikura Y, et al. Ann. Allergy 68:233, Pedesen S, et al. Eur. Respir. J. 12:30, Sheffer AL et al. J Allergy Clin Immunol 88:425, Wolthers OD et al. Pediatr 1992;89:839. Barnes PJ Am Rev Respir Dis 1993; 48: 511. Busse WW. Am. J. Respir. Crit. Care Med. 151: 1675, Johnston SL: Clin. Exp. Allergy 1996; 26:989. Mossad SB. Br. Med. J. 317:33, KK 1994 Kraneveld AD, et al. Am. J. Respir. Crit. Care Med. 156:367,1997 Yasui K, et al. J. Clin. Invest. 100:1677,1997. Shichijo M, et al. J. Allergy Clin. Immunol. 103:421, : 1993;38:44 Nomura I, et al. J. Allergy Clin. Immunol. 104:441,1999. Th1 Th2 66
68 Grewe M et al.: Lancet. 343:25,1994 Sampson HA. J. Allergy Clin. Immunol. 103:717, Shicerer SH, Sampson HA. J. Allergy Clin. Immunol. 104:114, Hong SJ, et al. J. Allergy Clin. Immunol. 104:473,1999. Eotaxin Mochizuki M et al. J. Immunol. 160:60,1998 Fukagawa K, et al. J. Allergy Clin. Immunol. 103:1220, CpG Klinman DM, et al. Immunity 11:123, 1999 Hartmann G, et al. Proc. Natl. Acad. Sci. USA 96,9305, Chanock SJ, Foster CB. J. Clin. Invest. 104: ,1999 Silver LM Reiss M, Straughan R ( ): 1999 DNA
0.02ml IgE RAST MAST CAP 2
( ) 1 0.02ml IgE RAST MAST CAP 2 3 1963 30 4 1986 20 39 IgE 30% 1988 54.7% IgE 47.6% 1990 892 IgE 27% 12% 1995 2379 1995 8 15 1996 1 12 2335 98.5% 2335 24 61 47 44.0 1 1) 2335 613 26.3% 2 5 613 43.4 44.2
untitled
28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS
untitled
. 23 3 2 1 2 3 21 21 22 9 1 23 18 4 5 6 5 40 20 7 1 1 8 9 10 11 12 50cm 13 10 11 14 2011 3 11 15 16 ml mm tel 079-557-0039 & fax 079-557-1888 17 248-240- 98-48- 170-98- 98- ml 85-1,085-18 19 20 21 22 23
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 5 2 5 24 () () () () () 1 1 150 50 50 1 1 ( 15,000 ) 150 ( 15,000 ) 100 50 50 1 1 ( 6,000 ) 150 ( 6,000 ) 100 50 50 1 1 150 1 1 150 100 0.25
日本皮膚科学会雑誌第121巻第11号
β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis
Novel chemical mediators in the resolution of inflammation Charles N. Serhan Key words E-mail : marita@nih.go.jp Charles N. Serhan Brigham & Women's Hospital/Harvard Medical School 1) Serhan, C. N.,
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.
untitled
~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/
2007050781......_.L.O...z.W
a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab
ニュースレター10-1.indd
The Japanese Society of Immunotoxicology 101192005 aaaa 12 2005172021 1-1-1 Tel. 03-5841-8205 / Dr. R.H. Pieters () "Immunotoxicology of therapeutics associated with allergy and autoimmunity" 2005 In
喘息について\(公健協会宛02-5作成\)
Q & A Q & A 1.? 20 2. 1) 2) 3) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 8) 9) 3. NHK ( ) 4 10 1 200mg ( ) ( 1 ) 4. ( ) ( ) 5. ( ) ( ) 6. β 2 ( ) 7. ( ) 1 8. 1. 2. 3. 4. 5. 6. 7. 8. 9. 2 5 7 1. 1 10 1) 2) 3) 30
Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : takaiwa@nias.affrc.go.jp 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.
後期化学_01_濃度
2011 ( ) 1 4 1 100 g g % * 1 100 g 1 g 1 % * 2 (1 g)/(100 g) = 0.01 = 1 % 100 g 100 g 99 g 100 g 1 g 1 % 2.5 g 50 g (2.5 g)/(50 g) = 0.050 = 5.0 % 100 ml g 1 %(w/w) wt% % %(w/v) % / 2 % SI 2 / % 100 ml
jcvp試験問題HP.indd
22 18 JCVP 1 G a e 1 G 1. A. B. C. D. P450 E. SOD c G 2. A. B. C. mrna D. E. G 3. G 4. A. B. ATP C. D. E. a A. B. C. 25 nm D. 10 nm E. 4 6 nm c d G 5. G 6. G 7. A. B. SOD C. D. E α E. d a. b. c. d. e.
ÿþ
インターロイキン インターロイキンは リンパ球や単球 マクロファージなどの免疫反応への寄与が知られる白血球から産生されることから 細胞間 ( inter-) 白血球 ( leukocyte -leukin) より Interleukin と名づけられました 現在までに 30 種類以上のインターロイキンが同定され 発見された順番に番号が付与されており 中にはケモカイン ( IL-8) やインターフェロン
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD
Immunocompromised Children 24 RS24 24 RS 24 RSRespiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 1 RS 28 2935 12 6 RS BPD 246 1 1 CHD 24 24 24 2 RS [1] [1.1] RS 24 RS T DiGeorge Wiskott- Aldrich
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
日本皮膚科学会雑誌第121巻第14号
World J Surg Burns Burns JTrauma Lancet Lancet Surg Gynecol Obste J Burn Care Rehabil BMJ Pediatr Emerg Care The Treatment of Burns Burns, A Team Approach Surg Gynecol Obstet NEnglJMed J Burn Care Rehabil
ab c d 6 12 1:25,000 28 3 2-1-3 18 2-1-10 25000 3120 10 14 15 16 7 2-1-4 1000ha 10100ha 110ha ha ha km 200ha 100m 0.3 ha 100m 1m 2-1-11 2-1-5 20cm 2-1-12 20cm 2003 1 05 12 2-1-13 1968 10 7 1968 7 1897
untitled
1907(40) 100 100 21 1 1 21 21 21 21 21 1891(M24) 1920(T9)1 2 1932(S7) 1947(S22) 1968(S43)12 2001(H13) 1955(S30) 1 24 9 7 22 43 13 2 100 6 200300t 1896M29 3876 1536 1 15 1907(M7) 11 6 1898(M31) 5 6 2 1912(M45)
2 (1) (2) SCI 2 SCI 2 24 2 12 2
2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1
) km 200 m ) ) ) ) ) ) ) kg kg ) 017 x y x 2 y 5x 5 y )
001 ) g 20 g 5 300 g 7 002 720 g 2 ) g 003 0.8 m 2 ) cm 2 004 12 15 1 3 1 ) 005 5 0.8 0.4 ) 6 006 5 2 3 66 ) 007 1 700 12 ) 008 0.315 ) 009 500 g ) kg 0.2 t 189 kg 17.1 kg 010 5 1 2 cm 3 cm )km 2-1 - 011
CAR-T実施
Building a Clinical CAR-T Program - Jichi Medical University Experience l l l Anti-CD3/28 mabs & IL-2: 29% Anti-CD3/28 beads: 66% Retroviral: 41% Lentiviral: 54% T-Flasks: 22% Static Culture Bags: 35%
本文／ＹＡ９２５５Ｃ
pp. E- -SH X in vitro in vivo -SH Structure-based drug development and medical biological application of cathepsin specific inhibitors Nobuhiko Katunuma Institute for Health Sciences, Tokushima Bunri University,Nishihamabouji,
untitled
Ref. No: KiG14B23-Kokushi22-R01 22 1/23 Ans Ans 1 75 64 74 8 75 75 Ans 9 75.1 2010 Ans Ans 1000 Ans 85cm 90cm 25 130mmHg 85mmHg 100mg/dl HbA1c 5.6 HDL 150mg/dl HDL-C 40mg/dl 1 3 Ans 1 (): 2 (): 3 (): 4
I
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
untitled
Fig.1 t O O N,N p n J J J J J t J J J J J J J J J J J t t J J J J J J J J J p Fig.2 p t Fig.3 Fig.4 synanti p Table1 Table2t Table2 synanti antisyn synanti synanti Fig.5 syn anti anti Fig.6 Table3 Table4
ŁRŁ¸•ñŁŁŁ‘
16 11 5 25mg 14 11 18 1 25mg 1 150,000 934 1 2 : 1-235-tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human γ1-chain Fc fragment), dimmer : : 1 235 236 467 G 1 γ1
VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)
中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml
NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008
8 20 symptom free 2 NEJM Clinical Practice fluticasone 1 2 fluticasone IgE 100U/ml 1819 Bostock 1 A Mycobacterium Toxoplasma
The Lancet, vol 378, Dec.17/24/31,2011 Alexander N Greiner USA Peter W Hellings, Guiseppina Rotiroti Glenis K Scadding The Lancet, Dec. 17/24/31, 2011 http://www.allergy.go.jp/allergy/guideline/04/index.html
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
H26分子遺伝-20（サイトカイン）.ppt
第 20 回 サイトカイン 1. サイトカインとは 2014 年 11 月 12 日 附属生命医学研究所 生体情報部門 (1015 号室 ) 松田達志 ( 内線 2431) http://www3.kmu.ac.jp/bioinfo/ クラスI IL-2~7, IL-9, IL-11, IL-12, IL-13, IL-15, Epo, GM-CSF etc. クラスII IFN-α, IFN-β,
1) Urlne analysls 7)Serologlcal exam. 1 1)ECG W.N.L. sugar 0% CRP (-) urobillnogen N(+) RA (+) 12)Renal function albumin 3(+) ASLO (-) PSP test 15' 40
A case of membranoproliferative glomerulonephritis accompanied with hyper IgM immunodeficiency Kenichiro SHIGEMOTO, Koji WADA, Naoki HAMAGUCHI, Akira HIRABAYASHI, Shunji TOI, Koji USUI, Michiko ARITA,
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
1 1 2 2 3 3 4 5 5 6 6 7 7 8 8 9 9 10 10. 11 1 12 1 13 2 13 3 8 13 4 14 5 14 6 14 7 15 8 15 1 17 2 22 3 24 4 24 1 33 2 42 1 49 2 50 3 50 4 56 1 60 2 88 3 93 1 95 2 96 1 98 2 100 1 100 2 104 3 105 4 105
ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)
日本皮膚科学会雑誌第120巻第5号
1 2 3 4 5 6 A B 1 2 α β 3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR
1996 papilloma virus 2001 Bowen2002 12 2003 2 2002 9 10 AIHA PSL1mg/kg BMAPRCA parvovirus B19 PVB19 DNA PCR PV IgM 4PVB19 PRCA MAPPVB19DNA DNA PRCA IVIG;20 50g/ IVIG PVB19AIHA steroid 15 20mg/day 2003
10中西_他.indd
Streptomyces mobaraensis N N N Sm b Sm N N Sm Sm Sm ' ' Sm Sm ak K k K bk k K Sm Sm a b S. mobaraensis a b a b Sm b b bb b b Sm Sm S. lividans ab Sm ab Sm ab ab ab ab SmSm S. lividansab S. lividans ab
Single slice helical CT CT 1 2005 1 4 1. CT Anti-Lung Cancer Association: ALCA 1-5) 1993 9 10 ALCA (Nawa 6) ) single slice helical CT 10mm CT 2. 1 (http://www.thoracic-ctscreening.org/jpn/index.html )
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
L
-G -VG -G -VG.MPa..MPa.1MPa..MPa 1.5MPa 1.5MPa 1.5MPa 1.5MPa 1 s 5 5 - -V 1.51MPa 1.5MPa s s..mpa.mpa 1.5MPa 1.5MPa - -V 1 s s 5 5 1 JISg/H 1. 1.5. 11 SLLBFFB SLLBFTC CCCCBTC..MPa 1.5MPa SLLBFFB CCCCBTC
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
住まい・まちづくり活動事例集
3 H15 1982 1988 5 H16.31 1 1 1 246 26 3 2003 11 21,417/ 65 17.91% 16.62%1.29 246 2 1 12 1246 5008026 30080 3 200803 120060 2 20013 1 1 21 11 19821988 199112003 13 1988 1 1991 28 3 1991 1993 1992 1 1995
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
RN201405_cs5_0418.indd
ISSN 1349-1229 No.395 May 2014 5 10 SPOT NEWS X2 FACE 13 14 TOPICS 15 16 IM-54 IM-54 IM-54 IM-54 IM-54 IM-54 NBD NBD NBD 02 RIKEN NEWS 2014 May STUDIO CAC 2004 2013 GFP IM-54IM-54 30 IM-54 IM-54 N O N
untitled
6 ( ). 1.. 1. 2. 3. 4. 5. ( ) 6. 7. 8. . 1. 1) 1 (12 3 ) 2 2) 3) ( ) ( ) 4) 2 () 2 2 3 5) ( ) R-Book ATLAS () 8 12 7 18 14 16 10 21 14 23 16 18 16 18 12 25 4 14 21 1 4 2 3 4 4 1 2 7 5 1 2 5 7 9 1 1 5 5
(a) (b) (c) (d) 1: (a) (b) (c) (d) (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4
![(a) (b) (c) (d) 1: (a) (b) (c) (d) (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4](/thumbs/91/105665060.jpg "(a) (b) (c) (d) 1: (a) (b) (c) (d) (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4")
1 vertex edge 1(a) 1(b) 1(c) 1(d) 2 (a) (b) (c) (d) 1: (a) (b) (c) (d) 1 2 6 1 2 6 1 2 6 3 5 3 5 3 5 4 4 (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4 1: Zachary [11] [12] [13] World-Wide
加藤茂孝先生
Shigetaka KATOW 2009 4 24 WHO 5 9 1 5 16 1 TV 6 12 6 11 WHO 6 4 5 12 E-mail : modern_media@eiken.co.jp 2009. 4. 28. http:idsc.nih.go.jpidwrkanjaweeklygraph01flu.html 0101-0051 - RIKEN Center of Research
3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: jiao@nacos.com 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB
5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
からだにeヘルシーレシピ 高血圧
We b e 3,5 00 7day 1. 2. & 3. 1 C O N T E N T S 2.6 0 1 0 5 0 7 1 0 9 17 2 2 2 3 CHECK&POINT! 2 5 24 1 2 7 e 2 9 e 3 1 webe 3 3 6 12 18 24 6 16 16g 111 1 6 1 2010 2010 18 20 3,970 18 1 400 2.6 01 02 140mmHg
色覚（初組4）.pm
733 3 1 520 1 8 4 0.2500 1 30012 1 AB 3 22 3 1 2 http://www.nig.ac.jp/labs/devgen/mou.html 734 1.1 360nm 830nm 380nm 780nm 540nm 580nm 660nm 540nm 660nm Log relative corneal sensitivity 0 1 2 400 500 600
Taro10-名張１審無罪判決.PDF
-------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -1- 39 12 23 36 4 11 36 47 15 5 13 14318-2-
WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
日本目録規則1987年版改訂2版第2章図書改定案
2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3
d-00
283-0105 298 TEL. 0475-76-0839 FAX. 0475-76-0838 400g 300 4950399167708 14 220g 300 4950399066780 Page 1 300g 200 4950399066766 100 400g 300 4950399167722 350g 160 4950399066735 100 600g 350 4950399167685
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
０９ Ｐ１０７〜１１８／木下 〃 芦塚 〃 稲
NK NK NK NK NK NK NK KT M NK NK KT M NK KT VTR SR SR SR SR SR SR KT NK NK FU M M A B C D E NK F G H I J I K M I I S R L L C C NKCL F C J J F M I J NK M M DY NK E E NK D D C D SR E D C C M NK NK SJ KK NK
コロイド化学と界面化学
x 25 1 kg 1 kg = 1 l mmol dm -3 ----- 1000 mg CO 2 -------------------------------------250 mg Li + --------------------------------1 mg Sr 2+ -------------------- 10
平成15 年度 大気汚染と花粉症の相互作用に関する調査研究（疫学研究）研究報告書
13 13 2 MEDLINE 2001 13 (1) 2002 1) 1996 1997 56,108 50,086 89.3% 5.2% 2002 2) 1998 6 9,471 4,035 42.6% 17,301 8,527 8,774 16.2% 17.3% 10 60 11.7% 19.8% 60 Okuda 2003 3) 10,920 12 3,370 390 28 2001 4 7
高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
drug development Toshimi Michigami, E-mail : michigami@mch.pref.osaka.jp Keiichi Ozono, E-mail : keioz@ped.med.osaka-u.ac.jp The progress in the research on vitamin D 1) McCollum, E. V. et al.:
1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,
( ) ー ( () ) 250 200 150 100 50 0 51 20 54 59 33 35 91 92 93 98 99 94 6 7 7 8 9 11 18 17 18 20 22 23 10 9 8 9 9 9 62 40 66 74 41 47 21 22 23 24 25 26 10 8 6 4 2 0 m3/s 7 41.3 5 5 18.4
本文／ＡＹ３８０Ｊ
MHC-II II MHC-II MHC- II CD T T TCR T T MHC-II MHC-II T MHC-II MHC-II MHC-II MHC-II Ii Ii-MHC-II MHC-II antigen processing compartment MIIC Regulation of cell surface expression of MHC-II in dendritic
km2 km2 km2 km2 km2 22 4 H20 H20 H21 H20 (H22) (H22) (H22) L=600m L=430m 1 H14.04.12 () 1.6km 2 H.14.05.31 () 3km 3 4 5 H.15.03.18 () 3km H.15.06.20 () 1.1km H.15.06.30 () 800m 6 H.15.07.18
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
›Ê”÷„¤‰ƒ‘−…j…–†[…X
ISSN 1347-0345 National Institute of Fruit Tree Science 2003. 10 2 2003. 10 3 19761986 1989 5219 1997 19 12 10 250 270g Brix 15 160.5g/100ml 1590 10 2003. 10 4 DNA DNASSR 44 41SSR SSR Simple Sequence Repeat=
Major Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128
Major Histocompatibility Complex 2018; 25 (: 128 138 抄録集 2018 4 14 A 3 128 MHC 2018; 25 ( HLA 2013 10.5 10 8 12 10 8 2016 CD34 + HLA NC 10 8 CD34 + CD34 + 10 6 NC10.5 2013.Apr 2014.Mar NC11 2014.Apr 2016.Jun
抗アレルギー効果のあるKW乳酸菌の発見と活用
KW3110 3 1 90 1983 6 1998 20 1989 Strachan BCG Lactobacillus Lactococcus Streptococcus Lactobacillus casei brevis johnsonii Th2 Th2 IL 4 B IgE IgE IgE IL-12 IL-12 Th1 Th1 Th2 Th2 Th1 Th2 KW 101 Th1/Th2
12331514 20131126 1 2 3 1 2 2 52495 4 1122 1 2 2 2 3 45 1 2 1 3 2 4 Z 8305 1962 8 4 2 1 2 2 35 3 12 1 2 32 4418 4 1 5 323 6 11111 332 5 342 6 1 23 4 2 3 7 3 2 3 25175 19132 8 2 1 1 2 3 4 5 6 7 2 1 2 3
Taro9-医薬品目次２０１２－１.PDF
5 0.1% 11 250mg 10 20mg 10 5ml 19 0.05% 13 1.25mg 10 1%5ml 19 10mg 10 0.2%100ml 18 25%50ml 9 2mg 17 5%250ml 9 20%25g 20 500 g 11 4 10g 20 Cap150mg 1 200mg 0 Cap90mg 5 20mg 10 10% 5 18 10mg 10 3%30g 20
1 1 1 11 25 2 28 2 2 6 10 8 30 4 26 1 38 5 1 2 25 57ha 25 3 24ha 3 4 83km2 15cm 5 8ha 30km2 8ha 30km2 4 14
3 9 11 25 1 2 2 3 3 6 7 1 2 4 2 1 1 1 11 25 2 28 2 2 6 10 8 30 4 26 1 38 5 1 2 25 57ha 25 3 24ha 3 4 83km2 15cm 5 8ha 30km2 8ha 30km2 4 14 60 m3 60 m3 4 1 11 26 30 2 3 15 50 2 1 4 7 110 2 4 21 180 1 38
JC-26_19352.indd
*KC-200 JI-2011 にフットコントローラーは付属されていません * 73 1 3 2 5 4 6 8 2 4 mm 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 0.5 0.8 1.0 1.3 1.5 1.8 2.0 2.5 3.0 *KC-200 JI-2011
本文／ＹＡ１３００Ｂ
pp. T T B T T T NKT T Ig B BCR T TCR Generation of T-lineage cells and their functions Kazunori Onoé Division of Immunobiology, Department of Pathophysiology, Institute for Genetic Medicine, Hokkaido University,
-2-
-1- -2- -3- 1 2 Pseudomonas avenae 34 36 3 25 20 4 1 200 300 2 18 20 5 24 10 ml 20 12 24 3-4- 4 32 33 3 1 60 30 3cm 1 2 1 3 1 3 2 3 1 2 1 1 3 2 2 1 300 3 1 5 0 1 1 2 2 3 3 4-5- 1nl 2n2 3n3 4n4 4N 100 N
(1) (2) (3) (4) (5) (6) (7) 4 (8) (9) () LAN 1 2 3 ( ) () () () 30 20 5 5 450 450 5 5 30 10 20 15 36 30 6 6 450 450 6 6 36 8 30 14 50 35 20 20 450 450 20 20 50 8 35 14 100 70 20 20 450 450
c c & % c 0 c N r l % *# 5 c c% c c % c c c % % c % % % c j % % % % % % % % &% &% % a % a &% c % cc % & s& cc c c & c & % c & c c & % % %c c %c & c % & % %c c %c & c % % % % % c c c a 28 % c% 13 5 6
09-12-15_1203new
12 15 12/15 1/14 E _ GC DC Y FB GA BF Y 2 g g a f Y b b d b b c c b b g a c e b f b - Y b b c a c C A C C Y f g a b c d e - g a b c d c ab ab b g bb fbbd 3 4 1 F B 1 DF C A A A 6 G F A B 5 GA 6 E BF G